Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1

Current Eye Research

Volumn 36, Issue 1, 2011, Pages 71-77

  Han, Song ^a   Wei, Wenbin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bim; Camptothecin; FOXO1; Retinoblastoma

Indexed keywords

BIM PROTEIN; CAMPTOTHECIN; LUCIFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DEPHOSPHORYLATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; WESTERN BLOTTING;

ANNEXIN A5; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; RETINAL NEOPLASMS; RETINOBLASTOMA; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 78650463600     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.510943     Document Type: Article

References (50)

1. Mahoney MC, Burnett WS, Majerovics A, et al. The epide miology of ophthalmic malignancies in New York State. Ophthalmology. 1990;97:1143-1147.
2. Suárez F, Jockovich ME, Hernandez E, et al. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine trans-genic model of retinoblastoma. Invest Ophthalmol Vis Sci. 2007;48:3437-3440.
3. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carbopla-tin. J Clin Oncol. 2003;21:2019-2025.
4. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321-1328.
5. Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348-1356.
6. Wilson TW, Chan HS, Moselhy GM, et al. Penetration of chemotherapy into vitreous is increased by cryo-therapy and cyclosporine in rabbits. Arch Ophthalmol. 1996;114:1390-1395.
7. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133:657-664.
8. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005;11:7569-7578.
9. Carcaboso AM, Bramuglia GF, Chantada GL, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: An alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci. 2007;48:3761-3767.
10. Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50:1492-1496.
11. Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication forks and topoisomerase I-DNA cleavable com plexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 1993;53:5908-5914.
12. Zunino F, Pratesi G. Camptothecins in clinical development. Expert Opin Invest Drugs. 2004;3:269-284.
13. Wang XZ, Beebe JR, Pwiti L, et al. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res. 1999;59:5842-5848.
14. Stathopoulos GP, Tsavdaridis D, Malamos NA, et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: A phase II study. Cancer Chemother Pharmacol. 2005;56:487-491.
15. Takahata T, Ookawa K, Suto K, et al. Chemosensitivity determinants of irinotecan hydrochloride in hepatocel-lular carcinoma cell lines. Basic Clin Pharmacol Toxicol. 2008;102:399-407.
16. Wang S, Zheng Y, Yu Y, et al. Phosphorylation of beta-actin by protein kinase C-delta in camptothecin analog-induced leu-kemic cell apoptosis. Acta Pharmacol Sin. 2008;29:135-142.
17. Hochster H, Kettner E, Kroning H, et al. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2005;5:257-262.
18. Moody TW, Fuselier J, Coy DH, et al. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides. 2005;26:1560-1566.
19. van Hattum AH, Pinedo HM, Schlüper HM, et al. The activity profle of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem Pharmacol. 2002;64:1267-1277.
20. Di Felice V, Lauricella M, Giuliano M, et al. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol. 1998;13:225-232. (Pubitemid 28329208)
21. Lauricella M, Giuliano M, Emanuele S, et al. Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells. Tumor Biol. 1998;19:356-363. (Pubitemid 28384461)
22. Suárez F, Jockovich ME, Hernandez E, et al. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine trans-genic model of retinoblastoma. Invest Ophthalmol Vis Sci. 2007;48:3437-3440.
23. Dalgard CL, Van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res. 2008;14:3113-3123.
24. Lee SY, Kim DK, Cho JH, et al. Inhibitory effect of bevaci-zumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol. 2008;126:953-958.
25. Lauricella M, Giuliano M, Emanuele S, et al. Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells. Tumor Biol. 1998;19:356-363. (Pubitemid 28384461)
26. Zhou Y, Gwadry FG, Reinhold WC, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: Microarray analysis of dose- and time-dependent effects. Cancer Res. 2002;62:1688-1695.
27. Ullmannova V, Haskovec C. Gene expression during camp-tothecin-induced apoptosis in human myeloid leukemia cell line ML-2. Neoplasma. 2004;51:175-180.
28. Chatterjee D, Schmitz I, Krueger A, et al. Induction of apop-tosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res. 2001;61:7148-7154.
29. LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002;8:274-281.
30. McDonald AC, Brown R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer. 1998;78:745-751.
31. Vasey PA, Jones NA, Jenkins S, et al. Cisplatin, camptoth-ecin, and taxol sensitivities of cells with p53-associated mul-tidrug resistance. Mol Pharmakol. 1996;50:1536-1540.
32. McDermott U, Longley DB, Galligan L, et al. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 2005;65:8951-8960.
33. Guo Y, Pajovic S, Gallie BL. Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma. Biochem Biophys Res Commun. 2008;375:1-5.
34. Pohl BS, Schon C, Rossner A, et al. The FoxO-subclass in Xenopus laevis development. Gene Expr Patterns. 2004;5:187-192.
35. Arden KC. Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol. 2006;41:709-717.
36. Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol. 2004;4:889-899.
37. Burgring BM, Kops GJ. Cell cycle and death control: Long live Forkheads. Trends Biochem Sci. 2002;27:352-360.
38. Furukawa-Hibi Y, Kobayashi Y, Chen C, et al. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal. 2005;7:752-760.
39. Lynch RL, Konicek BW, McNulty AM, et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res. 2005;3:163-169.
40. Berry E, Hardt JL, Clardy J, et al. Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1. Gynecol Oncol. 2009;112:331-336.
41. Li J, Yang L, Song L, et al. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. Oncogene. 2009;28:3 188-3196.
42. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120:2479-2487.
43. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857-868.
44. Mei Y, Xie C, Xie W, et al. Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. Neoplasia. 2007;9:871-881.
45. Liu Y, Xing H, Weng D, et al. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Cancer Lett. 2009;274:47-53.
46. Gillings AS, Balmanno K, Wiggins CM, et al. Apoptosis and autophagy: BIM as a mediator of tumor cell death in response to oncogene-targeted therapeutics. FEBS J. 2009;276:6050-6062.
47. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:856-859.
48. Kutuk O, Arisan ED, Tezil T, et al. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: Critical role of Noxa-mediated lipid peroxidation. Carcinogenesis. 2009;30:1517-1527
49. Jiang M, Wei Q, Wang J, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 2006;25:4056-4066.
50. Iwase M, Yoshiba S, Uchid M, et al. Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors. Int J Oncol. 2007;31:1141-1147